## Bruno Charbit

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5018666/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science, 2020, 369, 718-724.	12.6	2,374
2	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,983
3	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,749
4	Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis, 2020, 23, 611-620.	7.2	204
5	Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173 -activating mutations in 3 children. Journal of Allergy and Clinical Immunology, 2016, 138, 1752-1755.	2.9	192
6	Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E488-E497.	7.1	181
7	Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Medicine, 2018, 10, 59.	8.2	113
8	Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. Nature Immunology, 2021, 22, 1428-1439.	14.5	110
9	Platelet activation in critically ill COVID-19 patients. Annals of Intensive Care, 2021, 11, 113.	4.6	61
10	A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditis. Med, 2021, 2, 1072-1092.e7.	4.4	38
11	Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers. Journal of Experimental Medicine, 2021, 218, .	8.5	37
12	Regulation of the acetylcholine/α7nAChR anti-inflammatory pathway in COVID-19 patients. Scientific Reports, 2021, 11, 11886.	3.3	35
13	Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment. Science Advances, 2019, 5, eaav9019.	10.3	34
14	Human thymopoiesis is influenced by a common genetic variant within the <i>TCRA-TCRD</i> locus. Science Translational Medicine, 2018, 10, .	12.4	33
15	Type I interferon response and vascular alteration in chilblainâ€ŀike lesions during the COVIDâ€19 outbreak*. British Journal of Dermatology, 2021, 185, 1176-1185.	1.5	33
16	Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. Science Advances, 2021, 7, .	10.3	27
17	HMGB1 Is Involved in IFN-α Production and TRAIL Expression by HIV-1-Exposed Plasmacytoid Dendritic Cells: Impact of the Crosstalk with NK Cells. PLoS Pathogens, 2016, 12, e1005407.	4.7	25
18	Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. Journal of Allergy and Clinical Immunology, 2022, 149, 550-556.e2.	2.9	25

BRUNO CHARBIT

#	Article	IF	CITATIONS
19	Immune Profiling Enables Stratification of Patients With Active Tuberculosis Disease or <i>Mycobacteriu m tuberculosis</i> Infection. Clinical Infectious Diseases, 2021, 73, e3398-e3408.	5.8	18
20	Integrative genetic and immune cell analysis of plasma proteins in healthy donors identifies novel associations involving primary immune deficiency genes. Genome Medicine, 2022, 14, 28.	8.2	8
21	Defects in mucosal immunity and nasopharyngeal dysbiosis in HSC-transplanted SCID patients with IL2RC/JAK3 deficiency. Blood, 2022, 139, 2585-2600.	1.4	5
22	Early IFNÎ <sup>2</sup> secretion determines variable downstream IL-12p70 responses upon TLR4 activation. Cell Reports, 2022, 39, 110989.	6.4	4
23	Antibody-coated microbiota in nasopharynx of healthy individuals and IVIg-treated patients with hypogammaglobulinemia. Journal of Allergy and Clinical Immunology, 2020, 145, 1686-1690.e4.	2.9	3
24	Rhesus negative males have an enhanced IFNÎ <sup>3</sup> -mediated immune response to influenza A virus. Genes and Immunity, 2022, 23, 93-98.	4.1	2